CDK8/19抑制剂通过STAT6和p38 MAPK激活增强巨细胞中阿尔金酶-1的表达
Natsumi Mizuno1, Saki Shiga1, Yoshiyuki Tanaka1
1Department of Pharmacology, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Kanazawa 1757, Tobetsu, Ishikari, 061-0293, Japan.
European journal of pharmacology
|July 27, 2024
概括
使用BRD6989的环林依赖激酶 (CDK) 8/19抑制,增加了巨细胞中的阿尔金酶-1表达. 这一过程涉及激活STAT6和p38 MAPK,促进抗炎M2巨细胞的产生.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨细胞通过IL-4偏向M2表型,表达抗炎作用的阿尔金酶-1.
- 循环素依赖激酶 (CDK) 8/19抑制显示出抗炎潜力,与BRD6989等抑制剂开发.
- 对于CDK8/19抑制剂对巨细胞氨酶-1表达的影响尚不清楚.
研究的目的:
- 为了研究CDK8/19抑制剂对IL-4刺激的巨细胞中阿基因酶-1表达的作用.
- 阐明潜在的分子机制,包括STAT6和p38 MAPK信号通路.
主要方法:
- 用BRD6989.9治疗小鼠腹膜巨细胞和RAW264.7细胞.
- 评估阿尔金酶-1表达和CD206表面标记物的评估.
- 对STAT6酸化和p38 MAPK激活的分析.
- 使用p38 MAPK抑制剂来确认途径的参与.
主要成果:
- BRD6989显著增加了以依赖IL-4的方式转录的阿尔金酶-1表达.
- BRD6989增强了STAT6酸化,并激活了p38 MAPK,即使没有IL-4.
- 抑制p38 MAPK减弱了BRD6989引起的阿基因酶-1的增加.
- BRD6989提高了CD206表面表达,这是M2巨细胞标记物.
结论:
- 通过BRD6989抑制CDK8/19可以提高巨细胞中阿尔金酶-1的表达.
- 这种上调通过激活STAT6和p38 MAPK信号通路来调节.
- 抑制CDK8/19可以作为一种治疗策略,促进抗炎M2巨细胞的产生.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


